文献速递支持与姑息治疗

冷冻疗法预防紫杉烷类神经毒性的随机对照试验

Efficacy of cryotherapy in preventing taxane-induced neuropathy: the CryoPac randomised controlled trial.
PubMed 文献 · Ann Oncol · 2026-10-06

CryoPac 随机对照试验比较冷冻手套和袜子与常规护理预防紫杉烷所致周围神经毒性(CIPN)。共 268 例随机分组,217 例可分析。主要终点为治疗结束时 TNS≥2 的 CIPN 发生率,两组无显著差异(冷冻组 74% vs 对照组 84%,P=0.071)。冷冻组患者报告的手足麻木和刺痛症状较少,单丝触觉障碍减轻。

要点

  • 冷冻疗法未显著降低治疗结束时 TNS≥2 的 CIPN 发生率(74% vs 84%,P=0.071)。
  • 冷冻组 EORTC QLQ-CIPN20 显示手部刺痛、手/足麻木及精细操作困难均显著改善。
  • 冷冻组单丝触觉障碍显著减轻(P=0.006),但 CTCAE≥2 级 CIPN 无差异。

核心结论

  • 冷冻疗法未显著降低治疗结束时 TNS≥2 的 CIPN 发生率,但可减少患者报告的感觉症状和触觉障碍。

研究设计与样本

  • 随机对照试验,比较冷冻手套和袜子与常规护理,按中心和化疗方案分层,1:1 随机分配。
  • 纳入体能状态 0-1 的患者,排除既往紫杉烷治疗、CIPN 症状或基线 TNS>0 者。
  • 共 268 例随机分组,51 例脱落,217 例纳入分析(冷冻组 123 例,常规护理组 94 例)。

主要发现

  • 治疗结束时 CIPN 总体发生率为 78%,冷冻组 74%(91/123,95%CI 0.65-0.81),对照组 84%(79/94,95%CI 0.75-0.90),P=0.071。
  • EORTC QLQ-CIPN20 显示冷冻组手部刺痛(P=0.025)、手部麻木(P=0.025)、足部麻木(P=0.0005)及精细操作困难(P=0.006)均减少。
  • CTCAE≥2 级 CIPN 两组无差异(P=0.2),QLQ-C30 评分无差异,冷冻疗法未影响剂量调整。
  • 定量感觉测试显示冷冻组单丝触觉障碍减轻(P=0.006)。
  • 冷冻疗法依从率为 67%。

关键数值与推荐

  • 主要终点为治疗结束时 TNS≥2 的 CIPN 发生率。
  • 次要终点包括 CTCAE 5.0 版周围神经病变、EORTC QLQ-CIPN20 和 QLQ-C30 患者报告结局及定量感觉测试。

临床怎么用

  • 冷冻手套和袜子未能显著降低客观 CIPN 发生率,但可能改善患者报告的手足麻木和刺痛症状。
  • 该干预依从性为 67%,临床使用时需考虑患者耐受性和操作可行性。

局限性

  • 冷冻疗法依从率仅 67%,可能稀释干预效果。
  • 随访时间仅至治疗结束,长期获益尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating adverse effect of taxane chemotherapy. Currently, there is no established strategy for prevention or treatment. Smaller studies have suggested that cryotherapy may prevent CIPN. PATIENTS AND METHODS: We conducted a randomised controlled trial comparing usual care with cryotherapy using frozen gloves and socks during each taxane treatment. Participants were stratified by site and chemotherapy regiment and randomly assigned 1 : 1 to cryotherapy or usual care. Eligible patients had a performance status of 0-1. Exclusion criteria included prior taxane chemotherapy, symptoms of CIPN, and a baseline total neuropathy score (TNS) of >0. The primary endpoint was CIPN incidence at the end of treatment (EoT) defined as TNS of ≥2. Secondary endpoints included peripheral neuropathy evaluated with National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, patient-reported outcomes using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-CIPN20 and QLQ-C30, and quantitative sensory testing (QST). RESULTS: A total of 268 patients were randomly assigned; 51 dropped out, leaving 217 for analysis (cryotherapy 123, usual care 94 patients). CIPN incidence at EoT was 78% overall and did not differ significantly between the groups [cryotherapy: 91 of 123 (74%), 95% confidence interval (CI) 0.65-0.81; control: 79 of 94 (84%), 95% CI 0.75-0.90; P = 0.071]. Analysis of EORTC QLQ-CIPN20 subscales showed that the cryotherapy group had reduced tingling in hands (P = 0.025), numbness in hands (P = 0.025) and feet (P = 0.0005), and less trouble manipulating small objects (P = 0.006). No difference was found in CTCAE grade of ≥2 CIPN between groups (P = 0.2). QST showed that cryotherapy reduced tactile disturbance on the monofilament test (P = 0.006). No difference was observed in QLQ-C30 scores. Cryotherapy did not influence dose modifications. Compliance with cryotherapy was 67%. CONCLUSIONS: Cryotherapy did not significantly reduce CIPN incidence (TNS ≥ 2) at EoT but cryotherapy-treated patients reported fewer sensory symptoms and demonstrated reduced tactile disturbance. Longer follow-up may reveal benefits of cryotherapy for persistent CIPN, supporting possible clinical relevance.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lendorf ME, Bille MB, Krog SM, et al. Efficacy of cryotherapy in preventing taxane-induced neuropathy: the CryoPac randomised controlled trial. Ann Oncol. 2026. PMID: 42838271. doi:10.1016/j.annonc.2026.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。